Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
3 Months : From Dec 2019 to Mar 2020
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it has been recognized as a company that represents the Nasdaq Biotech Index in leading the nation in solving America’s Healthcare challenges following a year of several Company milestones, and invited to ring the Nasdaq Stock Market opening bell on January 13 in San Francisco, California.
“2019 was a momentous year for Co-Diagnostics,” commented Company CEO Dwight Egan. “Among other things, this past year saw the completion and CE marking of our first multiplex diagnostic, for Zika/dengue/chikungunya; the launch of several multiplex tests for the mosquito abatement market and recording our first domestic revenue from that vertical; an expansion of our license agreement with LGC, Biosearch for the CoPrimer™ technology; and of course the inauguration of our joint venture manufacturing facility in India, which was later followed by receiving IVD approval for 5 diagnostic assays from the India equivalent of the FDA. This latter milestone represents one of the most significant achievements of the Company to date in terms of growth, credibility of our technology platform, and anticipated financial impact.
“We extend our gratitude to all shareholders, investors, customers, and partners for their support, and hope you will join us as we build on these milestones to make 2020 the best year yet for CODX.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release may include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, and (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005155/en/
Head of Investor Relations